Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

Mandeep Atwal, Rebecca L. Swan, Chloe Rowe, Ka C. Lee, David C. Lee, Lyle Armstrong, Ian G. Cowell, and Caroline A. Austin

Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne, United Kingdom (M.A., R.L.S., C.R., K.C.L., I.G.C., C.A.A.) and Institute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, United Kingdom (D.C.L., L.A.)

Received May 16, 2019; accepted August 2, 2019

ABSTRACT

Topoisomerase II (TOP2) poisons are effective cytotoxic anticancer agents that stabilize the normally transient TOP2-DNA covalent complexes formed during the enzyme reaction cycle. These drugs include etoposide, mitoxantrone, and the anthracyclines doxorubicin and epirubicin. Anthracyclines also exert cell-killing activity via TOP2-independent mechanisms, including DNA adduct formation, redox activity, and lipid peroxidation. Here, we show that anthracyclines and another intercalating TOP2 poison, mitoxantrone, stabilize TOP2-DNA covalent complexes less efficiently than etoposide, and at higher concentrations they suppress the formation of TOP2-DNA covalent complexes, thus behaving as TOP2 poisons at low concentration and inhibitors at high concentration. We used induced pluripotent stem cell (iPSC)–derived human cardiomyocytes as a model to study anthracycline-induced damage in cardiac cells. Using immunofluorescence, our study is the first to demonstrate the presence of topoisomerase IIβ (TOP2B) as the only TOP2 isoform in iPSC-derived cardiomyocytes. In these cells, etoposide robustly induced TOP2B covalent complexes, but we could not detect doxorubicin-induced TOP2-DNA complexes, and doxorubicin suppressed etoposide-induced TOP2-DNA complexes. In vitro, etoposide-stabilized DNA cleavage was attenuated by doxorubicin, epirubicin, or mitoxantrone. Clinical use of anthracyclines is associated with cardiotoxicity. The observations in this study have potentially important clinical consequences regarding the effectiveness of anticancer treatment regimens when TOP2-targeting drugs are used in combination. These observations suggest that inhibition of TOP2B activity, rather than DNA damage resulting from TOP2 poisoning, may play a role in doxorubicin cardiotoxicity.

SIGNIFICANCE STATEMENT

We show that anthracyclines and mitoxantrone act as topoisomerase II (TOP2) poisons at low concentration but attenuate TOP2 activity at higher concentration, both in cells and in in vitro cleavage experiments. Inhibition of type II topoisomerases suppresses the action of other drugs that poison TOP2. Thus, combinations containing anthracyclines or mitoxantrone and etoposide may reduce the activity of etoposide as a TOP2 poison and thus reduce the efficacy of drug combinations.

Introduction

Human type II DNA topoisomerases (TOP2) are highly effective anticancer drug targets, but TOP2-targeting drugs (TOP2 poisons) can cause short- and long-term side effects, including neutropenia, therapy-related leukemia, and cardiotoxicity (Cowell and Austin, 2012; De Angelis et al., 2016). Anthracyclines target TOP2 and act via additional mechanisms, including lipid peroxidation, redox activity, and drug–DNA cross-link formation (Winterbourn et al., 1985; Bodley et al., 1989; Sinha et al., 1989; Capranico et al., 1990a; Gewirtz, 1999; Swift et al., 2006; Coldwell et al., 2008).

This work was supported by Breast Cancer Now [Grant 2012NovemberPhD11] and Bloodwise [Programme Grant 12031, Gordon Piller Studentship 13063].

This article has supplemental material available at molpharm.aspetjournals.org.

ABBREVIATIONS: DAPI, 4'-6-diamidino-2-phenylindole; dox, doxorubicin; DSB, double-strand break; epi, epirubicin; ICRF-187, 4-[2-(3,5-dioxo-1-piperazinyl)-1-methylpropyl]piperazine-2,6-dione; iPSC, induced pluripotent stem cell; kDNA, kinetoplast DNA; Pen/Strep, penicillin/streptomycin; TARDIS, trapped in agarose DNA immunostaining assay; TOP2, topoisomerase II; TOP2A, topoisomerase IIα; TOP2B, topoisomerase IIβ.

https://doi.org/10.1124/mol.119.117259

Mol Pharmacol 96:475–484, October 2019
to the accumulation of TOP2-DNA complexes within the cell that can result in cell death (Cowell and Austin, 2012). TOP2 catalytic inhibitors antagonize the action of TOP2 poisons and, therefore, may be used in combination with TOP2 poisons to reduce the side effects arising from TOP2 poison therapy (Reichardt et al., 2018).

Early in vitro studies and in cellulo studies of anthracycline interactions with TOP2 found a bell-shaped concentration dependence in the induction of DNA cleavage (Capranico et al., 1990a,b; Ferrazzi et al., 1991; Willmore et al., 2002). In vitro cleavage on pBR322 DNA showed doxorubicin cleavage at low concentrations, but less at higher concentrations (Tewey et al., 1984). The same effect was observed using in vitro end-labeled PMC41 DNA in cleavage assays (Bodley et al., 1989) or in vitro end-labeled SV40 DNA (Binaschi et al., 1998). In addition to suppression of in vitro cleavage, higher concentrations of doxorubicin and epirubicin attenuated teniposide and amsacrine (Capranico et al., 1990a,b). These early in vitro cleavage experiments used topoisomerase II enzyme purified from murine L1210 cells, which contained a mixture of the two isoforms topoisomerase IIα (TOP2A) and TOP2B. Using SDS/KCl to precipitate protein-DNA complexes, doxorubicin stabilized fewer protein-DNA complexes compared with an equitoxic dose of etoposide in the rat glioblastoma cell line C6 (Montaudon et al., 1997); no accumulation of TOP2-DNA complexes was observed in KB cells following doxorubicin treatment (Suzuki et al., 1997). Using immunologic assays specific for TOP2-DNA complexes, such as the trapped in agarose DNA immunostaining assay (TARDIS) and the in vivo complex of enzyme assay, which produce robust signals when cells are treated with etoposide, TOP2-DNA complexes were detectable under some conditions with mitoxantrone, idarubicin, epirubicin, and doxorubicin (Willmore et al., 2002; Errington et al., 2004; Smart et al., 2008; Hasinoff et al., 2016; Atwal et al., 2017). In this study, using the TARDIS assay, we confirm that mitoxantrone, doxorubicin, and epirubicin stabilize covalent TOP2-DNA complexes at lower concentrations, demonstrating poisoning activity, but that fewer complexes are stabilized at higher concentrations in cells, indicating inhibition of activity. Inhibition by mitoxantrone, doxorubicin, and epirubicin was compared with the catalytic inhibitor ICRF-193 (4,12-(3,5-dioxo-1-piperazinyl)-1-methylpropyl)piperazine-2,6-dione). In vitro experiments using recombinant TOP2A or TOP2B demonstrated that decatenation by either isoform was inhibited by mitoxantrone, doxorubicin, or epirubicin and that etoposide-induced cleavage by either isoform was attenuated by mitoxantrone, doxorubicin, or epirubicin. Biphasic poisoning/inhibition of TOP2 has potential implications for the pharmacokinetics of anthracyclines in cancer therapy.

**Materials and Methods**

**Reagents and Antibodies.** Doxorubicin, epirubicin, etoposide and mitoxantrone, dimethylsulfoxide, Tween 20, Triton X-100, and paraformaldehyde were purchased from Sigma-Aldrich (Dorset, UK). ICRF-193 was purchased from Biomol (Hamburg, Germany). Kinetooblast DNA (kDNA) was purchased from Insiaralis (Norwich, UK). Plasmid TCS1 was a gift from T. Hsieh, Duke University (Durham, NC) (Lee et al., 1989), and supercoiled plasmid DNA was purified using caesium chloride centrifugation. Recombinant human TOP2A and human TOP2B were produced as described by Wasserman et al. (1993) and West et al. (2000). Anti-TOP2 polyclonal antibodies raised in rabbits were used to conduct experiments. 4882 Anti-TOP2 was raised to topoisomerase II purified from calf thymus; this protein was a ~140-kDa N-terminal fragment lacking the C-terminal region based on partial peptide sequencing, and was a mixture of TOP2A and TOP2B (Austin et al., 1990). Antibodies 4566 and 4555 were raised to the C-terminal domain of recombinant human TOP2A (residues 1244–1531) or recombinant human TOP2B (residues 1263–1621), respectively. These antibodies were developed in house (see Supplemental Fig. 1). Anti-mouse yH2AX (catalog number 05-636) was obtained from Merck-Millipore.

**Decatenation Assays.** Two Hundred nanograms of kDNA was incubated in reaction buffer (50 mM Tris-HCl (pH 7.5), 125 mM NaCl, 10 mM MgCl2, 5 mM Dithiothreitol, and 100 μg/ml albumin), with or without drug, as indicated in the figure legends; the reaction volume was 20 μl, and reactions were initiated by the addition of TOP2A or TOP2B and incubated for 30 minutes at 37°C. Loading buffer was added and samples were run on a 0.8% gel in TBE buffer (100 mM Tris-borate (pH 8.3), 2 mM EDTA). Gels were stained with ethidium bromide after electrophoresis and visualized on a Bio-Rad EZ gel doc.

**DNA Cleavage Assays.** pTCS1 DNA substrate (3.9 μg) was incubated in reaction buffer (10 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 50 mM KCl, 150 μg/ml bovine serum albumin, and 1 mM ATP) in the presence or absence of mitoxantrone, doxorubicin, or epirubicin with or without etoposide for 30 minutes at 37°C. The reactions were initiated by the addition of 1.2 μg of TOP2A or TOP2B, and the reaction volume was 100 μl. Reactions were terminated by addition of SDS to 1%, followed by addition of EDTA to 25 mM and proteinase K to 0.5 mg/ml, and incubated for 60 minutes at 45°C. The DNA was precipitated overnight at −20°C following the addition of sodium acetate to 300 mM and the addition of two volumes of ethanol. The DNA precipitate was collected by centrifugation and the pellet air dried prior to resuspension in 15 μl TE buffer [10 mM Tris-HCl, 1 mM EDTA (pH 8.0)]; 5 μl of loading buffer was added, and the samples were heated to 70°C for 2 minutes prior to running on a 0.8% agarose gel in TAE buffer (40 mM Tris, 2 mM EDTA and 0.1% (w/v) glacial acetic acid (pH 8.3)) in the presence of ethidium bromide. Gels were visualized on a Bio-Rad EZ gel doc and bands were quantified by ImageLab v.5.2.1 (Bio-Rad).

**Cell Culture.** NB4 and K562 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin (Thermo Fisher Scientific, Paisley, UK). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. Experiments were conducted on exponentially growing cells (10⁶ cells/ml). NB4 (ACC-207) and K562 (CCL-243) cell lines (Lozzio and Lozzio, 1975; Lanotte et al., 1991) were originally sourced from the German Collection of Microorganisms and Cell Cultures GmbH and American Type Culture Collection, respectively. Cells were routinely tested for mycoplasma infection.

Undifferentiated induced pluripotent stem cells (iPSCs) were maintained in feeder-free culture with GFR Matrigel (Corning) and mTeSR1 (StemCell Technologies, Cambridge, UK) with 1% penicillin/streptomycin (Pen/Strep); these cells were tested monthly for mycoplasma and were originally sourced from Lonza (Basel, Switzerland). Differentiation to induced pluripotent stem cell–derived cardiomyocytes was performed using an established protocol followed by metabolic purification (Lian et al., 2013; Tohyama et al., 2013). In brief, iPSCs were cultured as described earlier to form a confluent monolayer; at this point (day 1 of the protocol), the medium was changed to a base differentiation medium consisting of RPMI 1640 supplemented with B27 minus insulin and 1% Pen/Strep (Life Technologies) and 9 μM CHIR99021 trihydrochloride (Tocris, Abingdon, UK). On day 2, the medium was changed to base medium. On day 4, the medium was changed to a mixture of fresh basal medium and the existing medium from the culture in a 1:1 ratio; this was supplemented with 5 μM IWP2 (Tocris). The medium was changed to base medium on day 6, and on day 8 the medium was changed to...
maintenance medium consisting of RPMI 1640 supplemented with 2% B27 and 1% Pen/Strep. On day 10, the medium was changed to metabolic purification medium consisting of RPMI 1640 without glucose, supplemented with 2% B27 and 1% Pen/Strep. On day 15, the medium was replaced with maintenance medium. Thereafter, the maintenance medium was changed every 2 to 3 days. Cardiomyocytes generated using this protocol were characterized by fluorescence-activated cell sorter analysis of SIRPA gene expression (Dubois et al., 2011) followed by quantitative polymerase chain reaction quantification of sarcomeric marker genes (ACTN2, TNNT2, TNNI3, MYH6, and MYH7) and detection of their respective proteins by immunohistochemistry (data not shown). Cardiomyocyte function was assessed by observation of spontaneous contraction and recording spontaneous calcium transients.

**TARDIS Assay.** The TARDIS assay was used to quantify the level of stabilized TOP2-DNA covalent complexes in situ, conducted as previously described (Willmore et al., 1998; Cowell et al., 2011). In brief, cells were treated for 1 hour with the desired TOP2 poison. Cells were pelleted (1000g, 5 minutes) and washed in ice-cold PBS. After recentrifugation, cells were mixed in an equal volume of molten 2% low melting point agarose (Lonza) in PBS and spread evenly onto agarose-coated slides. Agarose-embedded cells were lysed [1% (w/v) SDS, 20 mM sodium phosphate, 10 mM EDTA, pH 6.5], and noncovalently bound DNA proteins were removed using 1 M NaCl. Stabilized TOP2 covalent complexes were detected by immunofluorescence using anti-TOP2 rabbit polyclonal antibodies followed by Alexa Fluor 488-coupled anti-rabbit secondary antibodies (Thermo Fisher Scientific). Slides were counterstained with Hoechst 33258 (Thermo Fisher Scientific) to visualize DNA. Images were captured for Hoechst 33258 and Alexa Fluor 488 using an epifluorescence microscope (IX-81, 10× objective; Olympus) fitted with an Orca-AG camera (Hamamatsu) and suitable narrow-band filter sets. Image capture and automated slide scoring was performed using Velocity 6.3 software (PerkinElmer). In brief, acquired images were each processed to identify nuclei by thresholding the Hoechst 33258 signal. After filtering to separate or remove touching/overlapping objects (nuclei), the immunofluorescent signal emanating from each nucleus was determined to produce a table of integrated fluorescence per nucleus. Parameters to select individual nuclei were set up at the beginning of the analysis for one slide, and these parameters were then used for all other slides in the experiment. Data are represented using GraphPad Prism 8.0 or 8.1 (GraphPad Software) and R (The R Foundation, San Diego, CA).

**Immunofluorescence Analysis of yH2AX.** After drug treatment, cells were washed and pelleted in ice-cold PBS and spotted on poly-l-lysine-coated slides. Cells were fixed in 4% paraformaldehyde in PBS for 10 minutes and permeabilized using KCM + T buffer (120 mM KCl, 20 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.1% Triton X-100) for 15 minutes. After blocking in (KCM + T, 2% bovine serum albumin, 10% dry milk powder), cells were probed with anti-yH2AX in blocking buffer followed by Alexa Fluor 594 anti-mouse secondary antibodies. Slides were counterstained with DAPI (4’,6-diamidine 2 phenylindole). Images were captured for DAPI and Alexa Fluor 594 and quantification was performed using Velocity 6.3 (PerkinElmer) as described for the TARDIS assay.

**Statistics.** Statistical analysis was performed using GraphPad Prism 8.0. The details of the tests performed are given in the figure legends. For P values, * refers to P < 0.05, ** refers to P < 0.01, *** refers to P < 0.001, and **** refers to P < 0.0001. NS indicates not significant. Error bars in bar charts represent S.D. values.

**Results**

**Etoposide and Mitoxantrone Both Induce Stable TOP2-DNA Complexes but with Differing Concentration Responses.** TOP2-DNA covalent complexes stabilized by TOP2 poisons, such as etoposide, can be efficiently and specifically detected using the TARDIS assay (Willmore et al., 1998; Cowell et al., 2011). In this assay, cells treated with TOP2 poison are suspended in low-melting-point agarose, spread on glass microscope slides, and lysed in buffer containing 1% SDS and then extracted in high-salt buffer. This treatment removes most cellular constituents, leaving “nuclear ghosts” trapped in the agarose which consist of nuclear DNA and any covalently attached proteins. TOP2A or TOP2B covalent DNA complexes can then be detected and quantified on a single cell basis by immunofluorescence. In this way, the median fluorescent signal per nucleus and the distribution of nuclear signal intensities can be determined. For the archetypal epipodophyllotoxin TOP2 poison etoposide, TOP2A covalent complexes can be reproducibly detected with as little as 1 μM etoposide, and TOP2B complex induction can be detected from 10 μM in mouse and human cells (Willmore et al., 1998; Cowell et al., 2011; Atwal et al., 2017) (Fig. 1A). TOP2 complex levels increased with increasing etoposide concentration up to at least 100 μM etoposide. TOP2 complexes are processed in the cell to give rise to DNA double-strand breaks (DSBs) that elicit a DNA damage response, including the phosphorylation of histone H2AX. Etoposide-induced levels of H2AX phosphorylation followed a dose response similar to that observed for TOP2-DNA complexes (Fig. 1B).

Mitoxantrone is an anthracenedione TOP2 poison that, unlike etoposide, intercalates into DNA with a high affinity (Lown et al., 1984). We have previously shown that mitoxantrone also efficiently induces both TOP2A- and TOP2B-DNA complexes in murine cells, but the quantity of complexes platoues at approximately 1 μM mitoxantrone (Errington et al., 1999). We confirm this result here using human NB4 cells (Fig. 1C) and demonstrate that, at a higher concentration (20 μM), TOP2A and TOP2B complex levels are reduced, suggesting that mitoxantrone inhibits TOP2-DNA complex formation at elevated concentrations. This reduction in TOP2-DNA complexes at higher concentrations of mitoxantrone was mirrored in the level of H2AX phosphorylation. Levels of yH2AX signal peaked with 1 μM mitoxantrone and decreased at 10 and 20 μM mitoxantrone (Fig. 1D).

**Anthracyclines Targeting TOP2 Are Inefficient at Inducing Stable TOP2-DNA Complexes.** Similar to etoposide and mitoxantrone, anthracyclines, including doxorubicin (dox) and epirubicin (epi), are TOP2 poisons on the basis of their ability to increase the steady-state concentration of the covalent TOP2-DNA complexes by impeding religation of DNA (Pommier et al., 2010; Vos et al., 2011). Each of these drugs stimulates cleavage of DNA substrates by TOP2 in vitro assays (Bodley et al., 1989; Capranico et al., 1993; Binaschi et al., 1998). However, unlike etoposide and mitoxantrone, the anthracyclines have not been reported to induce the formation of large numbers of stable TOP2-DNA complexes in cells that can be detected using the TARDIS assay or the in vivo complex of enzyme assay (Montaudon et al., 1997; Willmore et al., 2002; Swift et al., 2006; Nitiss et al., 2012). For example, while the anthracycline idarubicin induced a small
A dose-dependent increase in TOP2A complexes up to 1 μM and a marginal increase in TOP2B complexes over control cells, at 20 μM fewer TOP2-DNA complexes were seen (Willmore et al., 2002). Doxorubicin-induced TOP2-DNA complexes were not detected in this previous TARDIS study (Willmore et al., 2002).

In this study, we were able to detect doxorubicin- and epirubicin-induced TOP2A complexes in human NB4 cells using the TARDIS assay (Fig. 2A). This discrepancy may be due to the improved sensitivity of the assay in the current study resulting from the use of brighter, more stable fluorochromes and more sensitive camera technology. However, median fluorescence levels per nucleus did not exceed 20% of the level recorded for the positive control treatment (100 μM etoposide), and no significant dox or epi signal was observed for TOP2B (Fig. 2A). For both dox and epi, only a small increase in median fluorescent signal was observed for TOP2A between 1.0 and 10 μM. Subsequent experiments were carried out at 10 μM for both drugs. In line with the reduced level of stabilized TOP2 complexes with 100 μM etoposide, dox and epi both resulted in lower γH2AX induction than etoposide (Fig. 2B). This is similar to a previous finding (Huelsenbeck et al., 2012) in rat glioblastoma cells, where doxorubicin-induced H2AX phosphorylation was maximal at 2 μM and was reduced compared with the extent of phosphorylation induced by 100 μM etoposide. Since TARDIS analysis provides fluorescence intensity data from individual nuclei, the resulting data can also be presented as the percentage of cells with a signal above a given threshold (Huelsenbeck et al., 2012). We chose 25% of the value of the median signal obtained for 100 μM etoposide as a convenient threshold. For TOP2A (4566), approximately 5% and 10% of 10 μM dox- and epi-treated cells exceeded this cutoff (Fig. 2C).

The data obtained for Figs. 1 and 2 involved treating cells for 60 minutes with TOP2 poison before carrying out the TARDIS assay. To determine whether the relatively low level of stable TOP2-DNA complexes observed with epi was due to slow complex formation compared with etoposide, a TOP2A TARDIS time-course experiment was performed. Median fluorescence levels induced by epi did not increase with drug incubation times from 30 to 120 minutes (Fig. 3A). The TARDIS assay data shown in Figs. 1, 2, and 3A used antibodies raised to the divergent C-terminal regions of the TOP2A and TOP2B proteins, which allows the two isoforms to be analyzed independently (4566 and 4555, respectively; see Supplemental Fig. 1). We were concerned that the low signal observed with the anthracyclines compared with etoposide could be due to epitope masking by post-translational
modification or rapid proteolytic removal of the C-terminal domain following anthracycline drug treatment. To test this possibility, we repeated the TARDIS assay with antibody 4566, which was raised to the conserved N-terminal 140 kDa of calf thymus TOP2 and detects both isoforms of human TOP2 (see Supplemental Fig. 1). Using this antibody, 10 and 100 μM etoposide produced a robust signal in the TARDIS assay. However, no significant increase in median fluorescence was observed for 10 μM dox or epi compared with the no-drug control (Fig. 3, B and C), whereas an intermediate level of signal was observed for 20 μM mitoxantrone. Considering the results obtained with antibodies 4566 (TOP2A C-terminal domain), 4555 (TOP2B C-terminal domain), and 4882 (TOP2A and TOP2B N-terminal 140 kDa), the low anthracycline-induced TOP2A signal and lack of TOP2B signal in the TARDIS assay are not likely to be due to loss or masking of the C-terminal domain, indicating inefficient trapping of stable TOP2 complexes by dox and epi.

**Doxorubicin, Epirubicin, and Mitoxantrone Can Inhibit Stable TOP2-DNA Complexes in Competition Assays.** Various lines of evidence, including in vitro DNA cleavage data, H2AX phosphorylation, and TARDIS data (Bodley et al., 1989; Willmore et al., 2002; Smart et al., 2008; Huelsenbeck et al., 2012), support the idea that intercalating anthracycline TOP2 poisons and mitoxantrone inhibit TOP2 activity at higher concentrations. Competition between poisoning and inhibition may then explain the relatively inefficient generation of stable TOP2-DNA complexes by anthracyclines. To further study this, etoposide-induced TOP2 complexes were quantified using the TARDIS assay in NB4 cells that had been preincubated with 10 μM dox, 10 μM epi, 20 μM mitoxantrone, or the well characterized bisdioxopiperazine TOP2 catalytic inhibitor ICRF-193 (100 μM) (Patel et al., 2000). As noted previously, the anthracyclines on their own induced a low TOP2A signal compared with that obtained with etoposide, whereas 20 μM mitoxantrone alone induced a small but significant TOP2A signal. ICRF-193 did not induce TOP2A or TOP2B complexes significantly above basal levels. However, preincubation with each of these drugs significantly inhibited both TOP2A and TOP2B covalent complex formation by etoposide (Fig. 4, A and B). Indeed, the level of inhibition achieved by the anthracyclines and mitoxantrone was similar to that observed for ICRF-193. Since NB4 cells contain a high level of myeloperoxidase activity, which increases TOP2 complex formation via oxidative activation of etoposide, we repeated the experiments shown in Fig. 4, A and B using the myeloperoxidase nonexpressing cell line K562 (Fig. 4, C and D). Very similar results were observed in K562 cells; the anthracyclines efficiently inhibited etoposide-induced TOP2A and TOP2B complex formation and TOP2A complexes at 100 μM etoposide.

Since TOP2 complexes are processed in cells to DSBs that elicit γH2AX formation, we also determined the ability of dox, epi, and mitoxantrone to inhibit etoposide-induced H2AX phosphorylation. As observed in Fig. 2B, the anthracyclines alone at 10 μM led to H2AX phosphorylation (Fig. 5); however, no signal above background was observed for 100 μM ICRF-193. Levels of histone H2AX phosphorylation induced by 10 μM etoposide were not significantly increased or decreased by pretreatment with dox or epi compared with etoposide alone. Whereas dox and epi alone produce an H2AX signal, no additive effect on DSB formation was observed when the anthracyclines were coincubated with 10 μM etoposide. In addition, H2AX phosphorylation induced by 10 μM etoposide was not reduced by anthracycline treatment. However, preincubation with epi, but not dox, did significantly reduce the level of H2AX phosphorylation by approximately 25% following treatment with 100 μM etoposide. In contrast, etoposide-induced H2AX phosphorylation was strongly suppressed by mitoxantrone at both concentrations of etoposide. Indeed, this suppression was greater than that observed for ICRF-193 with 100 μM etoposide, although the efficacy of inhibition by ICRF-193 may be limited by its solubility in aqueous solution.

**Doxorubicin Failed to Induce Detectable TOP2-B-DNA Complexes in Cardiomyocytes Derived from iPSCs but Did Suppress Etoposide-Induced Complex Formation.** Although anthracyclines are widely used and effective anticancer drugs, their side effect profile includes potentially serious cardiac damage (van Dalen et al., 2005). Using iPSC-derived cardiomyocytes, we examined the expression of TOP2B and TOP2A by immunofluorescence. As anticipated for fully differentiated cells, only about 5% of the cardiomyocytes expressed significant levels of TOP2A, but all...
cells expressed abundant TOP2B (Fig. 6A). Whereas 100 μM etoposide efficiently induced TOP2B-DNA complexes in the cardiomyocyte cells, doxorubicin did not induce TOP2B complexes significantly above background levels (Fig. 6B). Moreover, preincubation with 10 μM doxorubicin suppressed etoposide-induced TOP2B complexes in cardiomyocyte cells, confirming that doxorubicin attenuates TOP2 activity in cardiomyocytes. Thus, the inhibition observed by doxorubicin treatment is not limited to a single cell type.

**In Vitro Inhibition of TOP2 Decatenation Activity by Mitoxantrone, Doxorubicin, Epirubicin, or ICRF-193.** In vitro, TOP2 decatenation activity can be analyzed using highly catenated kDNA. As shown in Fig. 7, high-molecular-weight kDNA remains in the well of an agarose gel (first lane of each panel), and in the absence of drugs, TOP2A and TOP2B catalyze the decatenation of kDNA, resulting in the migration of decatenated circles into the gel (second lane of each panel). However, addition of mitoxantrone, dox, or epi resulted in a decline in the TOP2-mediated decatenation activity with increasing concentrations of drugs (Fig. 7). The effect of the catalytic inhibitor ICRF-193 is shown for comparison.

**In Vitro Attenuation of Etoposide-Induced DNA Cleavage by Mitoxantrone, Doxorubicin, or Epirubicin.** Data generated using two leukemia cell lines (NB4 and K562) and iPSC-derived cardiomyocytes strongly suggest that mitoxantrone, dox, and epi attenuate TOP2 activity, thereby...
blocking the formation of the TOP2-DNA covalent complex which prevents the action of the TOP2 poison, etoposide (Figs. 4–6). To further clarify this, we conducted in vitro DNA cleavage assays to analyze the effects of etoposide-induced TOP2-mediated DNA cleavage in the presence of mitoxantrone, dox, or epi. Cleavage experiments were performed using supercoiled plasmid DNA substrate TCS1 in the presence of etoposide and with varying concentrations of mitoxantrone, doxorubicin, or epirubicin. Increasing concentrations of mitoxantrone, doxorubicin, or epirubicin attenuated etoposide-induced plasmid cleavage in a concentration-dependent manner (Fig. 8). Etoposide-induced DNA cleavage of both isoforms was reduced by 50% or greater at concentrations between 4 and 6 \( \mu \text{M} \) mitoxantrone, doxorubicin, or epirubicin.

**Discussion**

This study aimed to evaluate the possible consequences of combining several TOP2-targeting drugs, some of them used in combination in current treatment protocols, in cancer cells with differing characteristics and in iPSC-derived human cardiomyocytes. We used the TARDIS assay to investigate the poisoning of TOP2-DNA complexes by the clinically relevant anthracyclines, doxorubicin and epirubicin, as well as the anthracenedione mitoxantrone. Stabilized TOP2-DNA complexes were detected, albeit at low levels, following treatment of NB4 cells with doxorubicin or epirubicin, consistent with earlier studies.

Unlike etoposide, which stabilized TOP2-DNA complexes in a concentration-dependent manner in NB4 cells, mitoxantrone produced a bell-shaped curve whereby levels of TOP2A- and TOP2B-DNA complexes increase up to 10 \( \mu \text{M} \) but were lower at 20 \( \mu \text{M} \). This suggests that mitoxantrone acts as a TOP2 poison at lower concentrations and has inhibitory activity at higher concentrations, as previously shown for idarubicin (Willmore et al., 2002). Willmore and colleagues also demonstrated inhibition by idarubicin using the TARDIS competition assay. Specifically, preincubation of cells with higher concentrations of idarubicin inhibited the etoposide-induced stabilization of TOP2-DNA complexes. In the current study, we also used the TARDIS competition assay to evaluate the activity of doxorubicin, epirubicin, and mitoxantrone as inhibitors for both isoforms of TOP2. TOP2 catalytic inhibitors reduce the level of etoposide-stabilized complexes, as they result in fewer “active” TOP2 molecules to bind and cleave DNA. Indeed, preincubation with ICRF-193, a well-established catalytic inhibitor of TOP2, substantially reduced the level of etoposide-induced TOP2 poisoning. Preincubation with doxorubicin, epirubicin, or mitoxantrone also significantly reduced levels of etoposide-induced TOP2A- and TOP2B-DNA complexes (Fig. 4). This supports the notion that anthracyclines and mitoxantrone can attenuate TOP2 activity, as suggested previously by in vitro cleavage studies (Capranico et al., 1990a,b). As doxorubicin, epirubicin, and mitoxantrone are DNA intercalators, the inhibition observed at higher concentrations may be due to DNA intercalation reducing access to DNA rather than direct enzyme inhibition as observed with ICRF-193. Consistent with this, Bodley et al. (1989) demonstrated that inhibition of TOP2-mediated DNA cleavage by a series of doxorubicin and daunorubicin...
congeners correlated with their intercalating capacity. In the present study (Fig. 7), we have shown that mitoxantrone, doxorubicin, and epirubicin each inhibit TOP2A- or TOP2B-mediated decatenation of kinetoplast DNA, an assay used to show inhibition of TOP2. Inhibition of TOP2B-catalyzed decatenation by doxorubicin was previously reported (Frank et al., 2016), and inhibition of TOP2A- and TOP2B-catalyzed decatenation was shown for doxorubicin, pixantrone, and etoposide by Hasinoff et al. (2016). We also show that in vitro cleavage of supercoiled plasmid DNA by etoposide is attenuated by mitoxantrone, doxorubicin, or epirubicin in a dose-dependent manner (Fig. 8); these in vitro experiments show effects at concentrations comparable to the cell-based assays and in patients. Notably, patient-derived Cmax concentrations for mitoxantrone, doxorubicin, and epirubicin were 0.7, 7, and 17 μM, respectively (Liston and Davis, 2017) and are comparable to the concentrations that attenuate etoposide cleavage (shown in Fig. 8).

The inhibition of TOP2 by doxorubicin, epirubicin, and mitoxantrone was also investigated using the γH2AX assay to measure levels of drug-induced double-strand DNA breaks. While etoposide induced the phosphorylation of histone H2AX in a concentration-dependent manner, γH2AX levels decrease with increasing concentrations of mitoxantrone above 1 μM. This is consistent with TARDIS data showing the decrease in TOP2-DNA complex levels at higher concentrations of mitoxantrone. Consistently, levels of etoposide-induced histone H2AX phosphorylation are significantly reduced when cells are preincubated with 20 μM mitoxantrone. In contrast, levels of doxorubicin-induced DSBs increased in a concentration-dependent manner. Furthermore, preincubation with doxorubicin did not affect the levels of etoposide-induced DSBs, despite significantly reducing levels of etoposide-induced TOP2-DNA complexes as measured by TARDIS assay. This supports the idea that doxorubicin-induced DNA damage occurs via additional mechanisms beyond TOP2 poisoning.
which could include DNA-adduct and free-radical formation (Gewirtz, 1999; Swift et al., 2006; Coldwell et al., 2008). This contrasts with mitoxantrone and ICRF-193, which significantly reduce the etoposide-induced γH2AX signal (Fig. 5), consistent with their action predominantly through TOP2.

Anthracyclines are used in many successful treatment protocols. However, patients treated with anthracyclines such as doxorubicin and epirubicin can develop serious cardiac complications, even at doses under the maximum recommended exposure limit. The mechanisms of cardiac toxicity are elusive, and many theories have been suggested because anthracyclines appear to act on more than one target. Whereas etoposide performs its cytotoxic action by mainly targeting TOP2 (Chen et al., 1984; Minocha and Long, 1984), it is believed that the anthracyclines (doxorubicin, epirubicin) and mitoxantrone use other mechanisms in addition to TOP2 poisoning for cytotoxicity (Tuteja et al., 1997; Gewirtz, 1999; Minotti et al., 2004; Evison et al., 2016). For example, doxorubicin treatment causes marked damage to mitochondria, yet mitochondrial targeting of doxorubicin eliminated the cardiac toxicity (Jean et al., 2015). Studies in murine cardiomyocytes and human pluripotent stem cell-derived cardiomyocytes have strongly implicated TOP2B in doxorubicin-induced cardiotoxicity (Zhang et al., 2012; Maillet et al., 2016). Lyu et al. (2007) proposed a model for the role of TOP2B in cardiotoxicity, where anthracycline-induced TOP2B-DNA covalent complexes are processed via proteasomal activity to exposed DNA-DSBs in cardiomyocytes. However, this study did not directly demonstrate the presence of anthracycline-induced TOP2-DNA complexes, and as we demonstrate here in lymphoblastoid cells, TOP2B-DNA complexes are induced very inefficiently in cells by anthracyclines. This suggests that the role of TOP2B in anthracycline-induced cardiotoxicity may be less straightforward. Elucidating the mechanism by which TOP2B expression leads to doxorubicin-induced cardiotoxicity may inform cardioprotection strategies in the clinic.

To further examine the possible effects of anthracyclines in light of their complicated mechanisms of TOP2 inhibition, we used iPSC-derived cardiomyocytes. Although these cells might show differences from the adult cardiomyocyte phenotype, mainly in terms of their metabolism, we show that most iPSC-derived cardiomyocytes do not express TOP2A, whereas TOP2B was expressed in all cardiomyocytes, which should also be true for adult terminally differentiated cardiomyocytes. In our experiments, doxorubicin (1 or 10 µM) did not induce TOP2B-DNA complexes above the background level in cardiomyocytes, even though complexes were efficiently induced by etoposide (Fig. 6). Furthermore, as was observed in NB4 and K562 cells, doxorubicin inhibited etoposide-induced TOP2B complex formation. This suggests that the mechanism of doxorubicin-mediated cardiotoxicity may involve inhibition of the normal cellular functions of TOP2B, such as transcriptional regulation, as opposed to TOP2B poisoning (Fig. 6). Given that TOP2A plays a major part in the cell death of cancer cells during anthracycline-containing chemotherapy while TOP2B appears less significant (Toyoda et al., 2008; Lee et al., 2016), the development of TOP2A-specific drugs may provide a means to reduce TOP2B-associated cardiotoxicity caused by anthracycline therapy (Mariani et al., 2015; Hasinoff et al., 2016) while maintaining drug efficacy.

The findings presented in this article have potential clinical implications as doxorubicin, epirubicin, and mitoxantrone are used in combination therapy with etoposide in a number of treatment regimes. In some regimes, etoposide is given concurrently with doxorubicin, epirubicin, or mitoxantrone. For example, dose-adjusted EPOCH, which is used to treat primary mediastinal lymphoma, contains rituximab, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin); In dose-adjusted EPOCH doxorubicin and etoposide are actually mixed in a single bag and infused together (Wilson et al., 2002). Even when the drugs are given sequentially, they could still be present at the same time as etoposide due to their long half-lives (14.2 hours for doxorubicin, 17 hours for mitoxantrone, and 33.7 hours for epirubicin) (Liston and Davis, 2017) and, therefore, may reduce its effectiveness. The data generated herein show that use of etoposide in combination with anthracyclines or mitoxantrone reduces the activity of etoposide as a TOP2 poison and thus has the potential to reduce the efficacy of drug combinations.

Acknowledgments
We thank Anna Jirkovská, Thomas Nicholls, Roderick Skinner, Simon Bomken, and Gareth Veal for helpful discussions.

Authorship Contributions
Participated in research design: Atwal, Cowell, Austin.
Conducted experiments: Atwal, Swan, Rowe, K. Lee.
Contributed new reagents or analytic tools: D. Lee, Armstrong.
Performed data analysis: Atwal, Rowe, Cowell.
Wrote or contributed to the writing of the manuscript: Atwal, Swan, Cowell, Austin.

References


